Evans School Policy Analysis & Research Group (EPAR)

The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.

An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions. 

The concept of global public goods represents a framework for organizing and financing international cooperation in global health research and development (R&D). Advances in scientific and clinical knowledge produced by biomedical R&D can be considered public goods insofar as they can be used repeatedly (non-rival consumption) and it is difficult or costly to exclude non-payers from gaining access (non-excludable). This paper considers the public good characteristics of biomedical R&D in global health and describes the theoretical and observed factors in the allocation R&D funding by public, private, and philanthropic sources.

As part of the Crops & Climate Change series, this brief is presented in three parts: 1) An evaluation of the importance of Sorghum and Millet in SSA, based on production, net exports, and caloric need, 2) A novel analysis of historical and projected climate conditions in Sorghum and Millet growing regions, followed by a summary of the agronomic and physiological vulnerability of Sorghum and Millet crops, 3) A summary of current resources dedicated to sorghum and millet, based on research and development investments and National Adaptation Programmes of Action. Our analysis indicates that sorghum and millets may become increasingly important in those areas of SSA predicted to become hotter and subject to more variable precipitation as a result of climate change. Although sorghum and millet are currently grown on marginal agricultural lands and consumed for subsistence by poorer population segments, climate change could render these drought- and heat-tolerant crops the most viable future cereal production option in some areas where other cereals are currently grown. Fewer international development resources are currently devoted to sorghum and millet than are devoted to other cereal grains, and current resource allocation may not reflect the increased reliance on these grains necessitated by projected climactic changes.